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Abstract
A 25-year-old, with type I Diabetes Mellitus with a previous diagnosis of Protamine Allergy but not
to human Insulin, started to notice anaphylactic reactions inmmediatly after bolus with Insulin. Skin
prick and intradermal test were positive to all insulins. Skin tests to other potential allergens
resulted negative. Examination after bolus of Human Insulin revealed urticaria. Daily insulin
requirement were around 2-2,4 U/Kg/day. Slow desensitisation with Aspart insulin, the insulin with
lowest size of skin test, was performed using subcutaneous insulin pump. Six months after the end
of desensitisation his daily insulin requirement decreased to 0.8 U/Kg/day and oral corticosteroids
are being reduced with no symptoms.
Introduction
Drug hypersensitivity reactions by IgE-mediated mecha-
nisms during therapies have been reported elsewhere.
Diagnosis is based in a meticulous clinical history, but
many times needs to be supported by skin and/or serolog-
ical tests and, even sometimes, drug provocation tests
since drug preparations may contain multiple potential
allergens that can trigger reactions, including drug itself,
carrier proteins [1] or additives [2]. Among drugs trigger-
ing allergy reactions, insulin allergy might be one of the
hot and controversial topics, since it is usually the only
known treatment in the case of patients suffering type I
diabetes. Although the prevalence of suspected insulin
allergy have been reported as high as 2.5% [3], diagnosis
should be more accurate since less than one third of
patients are finally diagnosed of true insulin allergy [4].
Case report
The patient is a 25-year-old builder with diabetes mellitus
who was diagnosed at 23 years of age. Treatment with
three daily injections of semi-synthetic human insulin
was initially tolerated (Neutral protamine Hagedorn -
NPH, Eli Lilly, Indianapolis, IN-: in the morning and in
the evening and Lispro -Eli Lilly, Indianapolis, IN- in
lunch-time). Glycosilated hemoglobin (HbA1c) controls
were around 10%. He gradually started to develop wheals
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and flare local reactions following his injections of insu-
lin. He was referred to Allergy Service of University Hospi-
tal NS Candelaria in April 2003. An initial exam at the
Outpatient Clinic revealed strong sensitisation to Nickel
Sulphate by patch test after 24, 48 and 96 hours. Sepa-
rately, skin prick test (SPT) and intradermal test (ID)
revealed sensitisation to Protamine (ID at 1:1000 dilu-
tion) but not to human insulin. Switch to Insulin without
Protamine (Lispro -Eli Lilly, Indianapolis, IN) and subcu-
taneous insulin pump were both recommended. He did
not observed any reaction for a 3-month period using
Human regular insulin. Next, he started to notice local
symptoms that progressively became worst. The symp-
toms included immediate episodes of wheals and flare
reactions far from insertion site of the catheter, with inten-
sive pruritus on palms and soles, and eventually dyspnea.
Then, he developed similar symptoms 2–3 hours after
bolus and occasionally some subcutaneos nodules.
Late 2004, he was hospitalised because ketoacidosis.
Metil-prednisolone (15 mg/day) and hydroxicine were
incorporated. Daily insulin requirement increased up to
2,4 U/Kg/day. He was reassessed at the Outpatient Clinic.
SPT were positive to all insulins except Aspart (Novo Nor-
disk, Denmark). Serial ID showed positive test with Aspart
at 1/100 dilution, Glargina (Aventis Pharma, Germany) at
1/100, zinc-crystalline insulin at 1/100, Lispro at 1/1,000
and Human regular insulin at 1/100.000. Skin tests to
other potential allergens resulted negative. Specific IgE to
protamine (0,43 kU/L), and bovine (2,5 kU/L), pork (3,9
kU/L) and human insulin (2,8 kU/L) were identified
(negative: <0.35 kU/L; UniCAP, Pharmacia Diagnostics,
Uppsala, Sweden). Controlled reexposure with a bolus of
Regular Insulin revealed non-tender swelling with flares
(5–6 cm of diameter) far from insertion of catheter with-
out other symptoms. A biopsy specimen of the skin
revealed subcutaneous edema with infiltrated cells,
including eosinophils.
One month later, he was hospitalised because another
cetoacydosis episode. As patient had the lowest grade of
sensitisation to Aspart Insulin according to skin tests, and
rapid insulin was needed, a desensitisation with Aspart
insulin was proposed to him. Metil-prednidsolone 30 mg/
day, but not hydroxicine, was maintained. Since his high
requirement of insulin and risk of ketoacidosis, treatment
with endovenous regular insulin was continued up to
achieve enough dose of Aspart insulin to sustain him.
After written and oral inform consent, desensitisation
using subcutaneous insulin pump [5] was performed in
16 sessions (6–7 doses per day). It was started with 0.001
U and increased 2-fold with intervals of 15–30 min,
repeating dose in the case of reaction (Table I). During
first consecutive 7 sessions patient suffered flare reactions
that were cleared up in few minutes without treatment
(figure 1, 2 and 3). During all process ketonemia did not
show significant changes and serum tryptase levels were
normal, although serum histamine did increase 2-fold.
Finally enough basal rate was maintained and "square
bolus" up to 20 U could be applied without reactions. Six
Table 1: Schedule of desensitization protocol by subcutaneous insulin pump with Aspart Insulin
DAY DOSE Reaction/n° PULSES TIME BETWEEN DOSES (min)
1 0,001 NO/1 15
1 0,005 NO/1 15
1/2 0,01 YES/4 15
1/2 0,02 YES/2 15
2/3 0,05 YES/2 15
2/3/4 0,1 YES/5 15
3/4/5 0,2 YES/6 15
3/4/5/6 0,4 YES/5 15
6/7 0,6 YES/4 15
6/7/8 0,8 YES/4 15
7/8/9 1 YES/3 30
8/9 1,4 YES/4 30
9/10 1,8 NO/4 30
9/10 2,5 NO/4 30
10/11 3 NO/4 30
11/12 3,5 NO/4 30
12/13 4 NO/4 30
13/14 7 NO/4 30
14/15 10 NO/4 30
15/16 15 NO/4 30
16 20 NO/4 30Clinical and Molecular Allergy 2005, 3:16 http://www.clinicalmolecularallergy.com/content/3/1/16
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months after the end of desensitisation his daily insulin
requirement decreased to 0.8 U/Kg/day and oral corticos-
teroids are being reduced (metilprednisolone 2 mg/48 h).
Discussion
Multiples cases of allergy to insulin components have
been described and reported [6] since it is the treatment
for type I diabetic patients. Currently, the prevalence of
reactions during insulin treatment seems to be around 2%
[3], but less than one third of reported events have been
considered related to insulin therapy [4]. Other multiples
causes include protamine [7-9], latex[10], cresol, zinc, etc.
IgE-mediated reactions have been reported with animal
[11] and human insulin [12-15] including semisynthetic
and biosynthetic insulins [5,16-21].
Many algorithms of insulin allergy diagnosis have been
published although diagnosis is merely based in compat-
ible clinical history and skin test [4] since many diabetic
patients can have positive skin test and serum antibodies
without clinical symptoms. Switch to insulin analogs has
markedly decreased the number of allergic episodes [22-
27], since allergenicity of insulin have been proposed by
chemical changes in the terminal of B chain [18], where
insulin analogs have the modified structure. For instance,
Lispro is insulin with lysine and proline in positions 28
and 29, respectively, of beta chain, instead of proline and
lysine as in human insulin. Aspart has aspartate in posi-
tion 28 of beta chain instead of proline (figure 4).
Glargine is insulin with arginine and proline in positions
28 and 29 respectively. However, these analogs have also
ability to induce allergic episodes[5,16-21,28] and
reduced immunogenicity has been more associated to its
faster absorption than any changes in the immunogenic
epitopes[25].
In this case, insulin pump [5,29] and slow desensitization
protocol[30] have demonstrated usefulness to tolerate
insulinen and has also helped to reduce insulin require-
ment as other authors have seen [31]. Although using
insulin pump alone have been associated to decrease in
insulin dosage [5], our patient was previously using insu-
lin pump with high doses of required insulin. Thus, we
could speculate that desensitisation have created a
decrease of insulin requirement.
In the near future, anti-immunoglobulin E treatment with
omalizumab will probably give another alternative to
these patients before transplantation [32]
Skin Reaction patient in day #2 Figure 2
Skin Reaction patient in day #2.
Skin Reaction patient in day #3 Figure 3
Skin Reaction patient in day #3.
Skin Reaction patient in day #1 Figure 1
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Terminal side of β chain (from aminoacid 23 to 30), including Insulin Receptor Binding (from aminoacid 23 to 25) of different  insulins Figure 4
Terminal side of β chain (from aminoacid 23 to 30), including Insulin Receptor Binding (from aminoacid 23 to 25) of different 
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